These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36260444)

  • 1.
    Indarti HT; Kristin E; Soedarsono S; Endarti D
    Int J Mycobacteriol; 2022; 11(3):261-267. PubMed ID: 36260444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline.
    Setyawan MF; Mertaniasih NM; Soedarsono S
    Acta Med Indones; 2023 Oct; 55(4):430-439. PubMed ID: 38213049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
    Souleymane MB; Decroo T; Mamadou S; Soumana A; Lawan IM; Gagara-Issoufou A; Adehossi E; Ortuño-Gutiérrez N; Lynen L; Rigouts L; de Jong BC; Van Deun A; Piubello A
    Int Health; 2023 May; 15(3):258-264. PubMed ID: 35420123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt.
    Afifi M; Amin W; Helal D; Ashmawy R; El-Maradny YA; Khalifa N; Ghazy RM
    Sci Rep; 2024 Jul; 14(1):16247. PubMed ID: 39009633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study.
    Sun WW; Yang M; Chen XH; Fan LC; Wu HY; Zhang SJ; Chen Y; Fan L
    Expert Rev Anti Infect Ther; 2024 Apr; 22(4):219-227. PubMed ID: 37982155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
    Hassane-Harouna S; Cherif GF; Ortuno-Gutierrez N; Cisse D; Camara LM; Diallo BD; Camara S; Bangoura AM; Lynen L; Decroo T
    PLoS One; 2020; 15(8):e0237355. PubMed ID: 32776969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia.
    Soeroto AY; Nurhayati RD; Purwiga A; Lestari BW; Pratiwi C; Santoso P; Kulsum ID; Suryadinata H; Ferdian F
    PLoS One; 2022; 17(1):e0263304. PubMed ID: 35089981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
    Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
    BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Jihwaprani MC; Sun Y; Rizky WC; Sula I; Saquib N
    Pulm Med; 2024; 2024():5542658. PubMed ID: 39157539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study.
    Soeroto AY; Pratiwi C; Santoso P; Lestari BW
    PLoS One; 2021; 16(2):e0246284. PubMed ID: 33556094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
    Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia.
    Hewison C; Bastard M; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Kiria N; Yegiazaryan L; Chumburidze N; Kirakosyan O; Atshemyan H; Qayyum S; Lachenal N; Varaine F; Huerga H
    Int J Tuberc Lung Dis; 2018 Jul; 22(7):766-772. PubMed ID: 29914602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
    Tack I; Dumicho A; Ohler L; Shigayeva A; Bulti AB; White K; Mbatha M; Furin J; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3563-e3571. PubMed ID: 33372989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
    Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
    Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
    Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
    Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
    [No Abstract]   [Full Text] [Related]  

  • 20. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.